Quantification of imatinib and related compounds using capillary electrophoresis‐tandem mass spectrometry with field‐amplified sample stacking
- 11 June 2020
- journal article
- research article
- Published by Wiley in Electrophoresis
- Vol. 41 (21-22) , 1843-1850
Abstract
A quantification method for imatinib (IM), its major metabolite N‐desmethyl imatinib (NDI), and a degradation by‐product was developed using CE–MS combined with an online concentration technique. The use of multiple reaction monitoring (MRM)–MS/MS further improved the sensitivity of this technology. Liquid–liquid extraction (LLE) using tertiary butyl methyl ether yielded high recovery and reproducibility for the pretreatment of serum samples. The recovery rate exceeded 83% for all three analytes, and was 90% for IM. To improve quantification results, a conductivity‐induced online analyte concentration technique, field‐amplified sample stacking (FASS), was used. The S/N ratios were improved at least 10‐fold when compared with conventional capillary zone electrophoresis. The detection limits were 0.2 ng/mL for IM, 0.4 ng/mL for NDI, and 4 ng/mL for the degradation by‐product. These results are superior to those previously obtained by other reported methods. The new method was validated in terms of its selectivity, intra‐ and interday repeatability and accuracy, and sample storage stability, following the guidelines issued by the European Medicines Agency. Considering the convenient pretreatment procedure (LLE), superior sensitivity, and fast analysis speed (<15 min), this method can be useful in the determination of imatinib levels in blood.Keywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada
This publication has 27 references indexed in Scilit:
- Progress with covalent small-molecule kinase inhibitorsDrug Discovery Today, 2018
- Small-molecule kinase inhibitors: an analysis of FDA-approved drugsDrug Discovery Today, 2016
- Pharmacologic monitoring and determinants of intracytoplasmic drug levelsBest Practice & Research Clinical Haematology, 2009
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyBlood, 2008
- Identification of imatinib mesylate degradation products obtained under stress conditionsJournal of Pharmaceutical and Biomedical Analysis, 2007
- Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood, 2006
- Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia PatientsJournal of Clinical Oncology, 2004
- Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588Cancer Chemotherapy and Pharmacology, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2002